Drug-Induced Liver Injury Associated with the Use of Everolimus in a Liver Transplant Patient

Figure 1

Patient’s liver enzyme levels and level of immunosuppression after receiving a liver transplant in July 2015. The blue arrow represents the date of the transplant and the shaded area between the red arrows represents the everolimus exposure period (start: 9/3/15; end: 12/1/15).